Literature DB >> 11895890

A view to a kill: signals triggering cytotoxicity.

Julie Y Djeu1, Kun Jiang, Sheng Wei.   

Abstract

Tumor immunity requires the participation of lymphocyte effector cells that display powerful processes to destroy malignant cells. Natural killer (NK) cells and CTLs, once activated, use the same lytic processes for mediating target cell death. However, they are triggered through distinctly separate antigen receptors. NK cells are currently known to express at least three families of receptors unrelated to the T cell receptor, i.e., NKG2, KIR, and NCR, to mediate cytotoxicity. This review provides a view to a kill, bringing together a unifying concept for a common signal pathway that dictates lytic function. What emerges is a specific Syk/Zap70 --> PI3K --> Rac --> PAK --> MEK --> ERK signal cascade triggered by target cell recognition, which is responsible for mobilizing the lytic granules containing perforin and granzyme B toward the contacted target cell.

Entities:  

Mesh:

Year:  2002        PMID: 11895890

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  34 in total

1.  Predicting cytotoxic T-cell age from multivariate analysis of static and dynamic biomarkers.

Authors:  Catherine A Rivet; Abby S Hill; Hang Lu; Melissa L Kemp
Journal:  Mol Cell Proteomics       Date:  2010-12-30       Impact factor: 5.911

2.  Dibutyltin activates MAP kinases in human natural killer cells, in vitro.

Authors:  Sabah O Odman-Ghazi; Abraham Abraha; Erica Taylor Isom; Margaret M Whalen
Journal:  Cell Biol Toxicol       Date:  2010-03-24       Impact factor: 6.691

3.  Immune-related, lectin-like receptors are differentially expressed in the myeloid and lymphoid lineages of zebrafish.

Authors:  Patoula G Panagos; Kimberly P Dobrinski; Xianghong Chen; Amanda W Grant; David Traver; Julie Y Djeu; Sheng Wei; Jeffrey A Yoder
Journal:  Immunogenetics       Date:  2006-02-09       Impact factor: 2.846

4.  Retention of viability, cytotoxicity, and response to IL-2, IL-15, or IFN-alpha by human NK cells after CD107a degranulation.

Authors:  Costin Tomescu; Jihed Chehimi; Vernon C Maino; Luis J Montaner
Journal:  J Leukoc Biol       Date:  2009-02-23       Impact factor: 4.962

Review 5.  Type 1 diabetes therapy beyond T cell targeting: monocytes, B cells, and innate lymphocytes.

Authors:  F Susan Wong; Li Wen
Journal:  Rev Diabet Stud       Date:  2012-12-28

6.  CD28-stimulated ERK2 phosphorylation is required for polarization of the microtubule organizing center and granules in YTS NK cells.

Authors:  Xi Chen; David S J Allan; Konrad Krzewski; Baoxue Ge; Hernan Kopcow; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

7.  TGF-β-inducible microRNA-183 silences tumor-associated natural killer cells.

Authors:  Sarah S Donatelli; Jun-Min Zhou; Danielle L Gilvary; Erika A Eksioglu; Xianghong Chen; W Douglas Cress; Eric B Haura; Matthew B Schabath; Domenico Coppola; Sheng Wei; Julie Y Djeu
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-28       Impact factor: 11.205

8.  A critical role for DAP10 and DAP12 in CD8+ T cell-mediated tissue damage in large granular lymphocyte leukemia.

Authors:  Xianghong Chen; Fanqi Bai; Lubomir Sokol; Junmin Zhou; Amy Ren; Jeffrey S Painter; Jinhong Liu; David A Sallman; Y Ann Chen; Jeffrey A Yoder; Julie Y Djeu; Thomas P Loughran; Pearlie K Epling-Burnette; Sheng Wei
Journal:  Blood       Date:  2008-12-15       Impact factor: 22.113

9.  A unique region of RILP distinguishes it from its related proteins in its regulation of lysosomal morphology and interaction with Rab7 and Rab34.

Authors:  Tuanlao Wang; Ka Khuen Wong; Wanjin Hong
Journal:  Mol Biol Cell       Date:  2003-12-10       Impact factor: 4.138

10.  Differently phosphorylated forms of the cortactin homolog HS1 mediate distinct functions in natural killer cells.

Authors:  Boyd Butler; Diana H Kastendieck; John A Cooper
Journal:  Nat Immunol       Date:  2008-06-29       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.